US6136310A
(en)
*
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
US6440418B1
(en)
*
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
EP0938334A4
(en)
*
|
1996-07-26 |
2004-12-15 |
Smithkline Beecham Corp |
IMPROVED METHOD FOR TREATING IMMUNE-MEDIATED SYSTEMIC DISEASES
|
GB9624038D0
(en)
*
|
1996-11-19 |
1997-01-08 |
Sandoz Ltd |
Organic compounds
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US7033589B1
(en)
*
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
WO1998058966A1
(en)
*
|
1997-06-24 |
1998-12-30 |
Norman Godin |
A composition for specific immunoprotection and method for obtaining said composition
|
US7189400B2
(en)
|
1998-03-17 |
2007-03-13 |
Genetics Institute, Llc |
Methods of treatment with antagonists of MU-1
|
US7198789B2
(en)
*
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
US6057128A
(en)
*
|
1998-03-17 |
2000-05-02 |
Genetics Institute, Inc. |
MU-1, member of the cytokine receptor family
|
US6528624B1
(en)
*
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
BR0008758A
(pt)
*
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
AU2001249182A1
(en)
*
|
2000-03-14 |
2001-09-24 |
Genetics Institute Inc. |
Use of rapamycin and agents that inhibit b7 activity in immunomodulation
|
WO2001094586A2
(en)
*
|
2000-06-06 |
2001-12-13 |
Idec Pharmaceuticals Corporation |
Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
AR035779A1
(es)
*
|
2001-02-06 |
2004-07-14 |
Genetics Inst Llc |
Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos
|
US6972324B2
(en)
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
GB2376466A
(en)
*
|
2001-06-14 |
2002-12-18 |
Mark Frewin |
TRX1 antibody
|
US7541443B2
(en)
*
|
2001-06-14 |
2009-06-02 |
Tolerrx, Inc. |
Anti-CD4 antibodies
|
WO2003006607A2
(en)
*
|
2001-07-10 |
2003-01-23 |
Idec Pharmaceutical Corporation |
Inhibition of apoptosis process and improvement of cell performance
|
GB2380127A
(en)
*
|
2001-09-26 |
2003-04-02 |
Isis Innovation |
Treatment of chronic joint inflammation
|
JP2005508915A
(ja)
|
2001-10-04 |
2005-04-07 |
ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー |
インターロイキン21受容体活性を調節する方法および組成物
|
JP2005535282A
(ja)
|
2001-11-16 |
2005-11-24 |
アイデック ファーマシューティカルズ コーポレイション |
抗体のポリシストロニック発現
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
EP1572936A2
(en)
*
|
2002-03-05 |
2005-09-14 |
Eli Lilly And Company |
Heterologous g-csf fusion proteins
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
US20040016010A1
(en)
*
|
2002-04-17 |
2004-01-22 |
Marion Kasaian |
IL-21 receptor knockout animal and methods of use thereof
|
ES2385032T3
(es)
*
|
2002-04-22 |
2012-07-17 |
Recopharma Ab |
Vacunas de polipéptido de fusión de mucina, composiciones y métodos de uso de las mismas
|
AU2003233008B2
(en)
*
|
2002-04-22 |
2008-04-24 |
Recopharma Ab |
Fusion polypeptides and methods for inhibiting microbial adhesion
|
CA2483474A1
(en)
*
|
2002-04-22 |
2003-10-30 |
Absorber, Ab |
Lewis y epitope modified polypeptide, or mucin fusion polypetide, tumor vaccines
|
ZA200500480B
(en)
*
|
2002-07-15 |
2006-10-25 |
Wyeth Corp |
Methods and compositions for modulating T helper (TH) cell development and function
|
NZ538629A
(en)
*
|
2002-08-09 |
2008-05-30 |
Recopharma Ab |
Mucin-immunoglobulin fusion proteins
|
CN100341573C
(zh)
*
|
2002-09-27 |
2007-10-10 |
唐纳士公司 |
用于预防和治疗获得性免疫缺陷综合症的协同组合物
|
PT2891666T
(pt)
*
|
2002-10-16 |
2017-09-22 |
Purdue Pharma Lp |
Anticorpos que se ligam ca 125/0722p associado a células e métodos para a sua utilização
|
ATE540978T1
(de)
*
|
2002-10-17 |
2012-01-15 |
Genmab As |
Humane monoklonale antikörper gegen cd20
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
EP1460088A1
(en)
*
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
WO2004089988A2
(en)
*
|
2003-04-03 |
2004-10-21 |
Protein Design Labs, Inc |
Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
|
NZ544165A
(en)
|
2003-06-11 |
2008-12-24 |
Wyeth Corp |
Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof
|
GB2406094B
(en)
*
|
2003-09-17 |
2007-06-06 |
Antisoma Plc |
Modified antibody comprising an amino acid substitution mutation which confers increased stability
|
CN1902228A
(zh)
*
|
2003-11-07 |
2007-01-24 |
安姆根有限公司 |
猴免疫球蛋白序列
|
EP1740946B1
(en)
*
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
MX2007001509A
(es)
*
|
2004-08-05 |
2007-03-27 |
Wyeth Corp |
Antagonismo de la actividad del receptor de interleuquina 21.
|
CA2589422A1
(en)
*
|
2004-10-14 |
2007-04-12 |
Recopharma Ab |
Compositions and methods for inhibiting h. pylori adhesion and infection
|
US7589182B1
(en)
|
2005-01-07 |
2009-09-15 |
Los Alamos National Security, Llc |
Anti-sulfotyrosine antibodies
|
US20060193849A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Antisoma Plc |
Biological materials and uses thereof
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
GT200600148A
(es)
*
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
BRPI0618488A2
(pt)
*
|
2005-11-10 |
2011-08-30 |
Receptor Biologix Inc |
proteìnas de fusão de ìntron de fator de crescimento de hepatócito
|
EP1951332A1
(en)
*
|
2005-11-10 |
2008-08-06 |
Schering Aktiengesellschaft |
Reduction of restenosis
|
US7495097B2
(en)
*
|
2005-11-23 |
2009-02-24 |
Brown University |
Rhodium quinonoid catalysts
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
AU2007208218A1
(en)
*
|
2006-01-23 |
2007-08-02 |
Recopharma Ab |
Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
|
US20090181041A1
(en)
*
|
2006-01-23 |
2009-07-16 |
Jan Holgersson |
Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
|
WO2007132355A2
(en)
*
|
2006-01-26 |
2007-11-22 |
Recopharma Ab |
Compositions and methods for inhibiting viral adhesion
|
EP2001510A4
(en)
*
|
2006-03-16 |
2010-06-09 |
Genentech Inc |
METHODS OF TREATING LUPUS USING CD4 ANTIBODIES
|
US20080279848A1
(en)
*
|
2006-03-16 |
2008-11-13 |
Genentech, Inc. |
Methods of treating lupus using CD4 antibodies
|
TW200806317A
(en)
*
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
AU2007252926A1
(en)
|
2006-03-23 |
2007-11-29 |
Absorber Ab |
Blood group antigens of different types for diagnostic and therapeutic applications
|
DK3056568T3
(da)
|
2006-03-31 |
2021-11-01 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
|
EP3345616A1
(en)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
CA2655205A1
(en)
*
|
2006-06-12 |
2007-12-21 |
Receptor Biologix Inc. |
Pan-cell surface receptor- specific therapeutics
|
TW200817438A
(en)
*
|
2006-08-17 |
2008-04-16 |
Hoffmann La Roche |
A conjugate of an antibody against CCR5 and an antifusogenic peptide
|
CL2008000707A1
(es)
|
2007-03-13 |
2008-09-22 |
Hoffmann La Roche |
Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
|
MY166021A
(en)
|
2007-03-22 |
2018-05-21 |
Biogen Ma Inc |
Binding proteins,including antibodies,antibody derivatives and antibody fragments,that specifically bind cd154 and uses thereof
|
TW200902708A
(en)
*
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
TW200902547A
(en)
*
|
2007-04-27 |
2009-01-16 |
Genentech Inc |
Potent, stable and non-immunosuppressive anti-CD4 antibodies
|
AR067584A1
(es)
*
|
2007-07-20 |
2009-10-14 |
Hoffmann La Roche |
Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
|
SG193868A1
(en)
|
2007-09-26 |
2013-10-30 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
JP5334319B2
(ja)
|
2007-09-26 |
2013-11-06 |
中外製薬株式会社 |
Cdrのアミノ酸置換により抗体の等電点を改変する方法
|
RU2010119556A
(ru)
*
|
2007-10-16 |
2011-11-27 |
Симфоген А/С (Dk) |
Композиции, содержащие оптимизированные мультимеры her1 и her3, и способы их применения
|
CN101939424B
(zh)
|
2007-12-05 |
2016-12-28 |
中外制药株式会社 |
抗nr10抗体及其应用
|
BRPI0909179A2
(pt)
|
2008-03-13 |
2015-08-25 |
Biotest Ag |
Composição farmacêutica, e, método de tratamento de uma doença autoimune.
|
EP2265643B1
(en)
*
|
2008-03-13 |
2016-10-19 |
Biotest AG |
Dosing regimen for treating psoriasis and rheumatoid arthritis
|
MX2010010026A
(es)
|
2008-03-13 |
2011-03-21 |
Biotest Ag |
Agente para tratar enfermedad.
|
CA2722127A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting shiga toxin and shiga-like toxin
|
WO2009136297A2
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting toxin a from clostridium difficile
|
JP2011520959A
(ja)
*
|
2008-05-23 |
2011-07-21 |
アルゴス・セラピューティクス・インコーポレーテッド |
新規可溶性cd83ポリペプチド、配合物および使用法
|
TW201016233A
(en)
*
|
2008-07-15 |
2010-05-01 |
Genentech Inc |
Methods of treating autoimmune diseases using CD4 antibodies
|
EP2331140B1
(en)
|
2008-08-11 |
2018-07-04 |
Nektar Therapeutics |
Multi-arm polymeric alkanoate conjugates
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
MX2011003335A
(es)
*
|
2008-09-29 |
2011-04-27 |
Biotest Ag |
Composicion para tratar enfermedad.
|
EP2350130B1
(en)
*
|
2008-10-31 |
2018-10-03 |
Wyeth LLC |
Purification of acidic proteins using ceramic hydroxyapatite chromatography
|
JP5511686B2
(ja)
|
2008-12-26 |
2014-06-04 |
協和発酵キリン株式会社 |
抗cd4抗体
|
EP2409991B1
(en)
|
2009-03-19 |
2017-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
Chugai Pharmaceutical Co Ltd |
Antibody constant region change body
|
FR2945538B1
(fr)
|
2009-05-12 |
2014-12-26 |
Sanofi Aventis |
Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
|
SG176074A1
(en)
|
2009-05-15 |
2011-12-29 |
Chugai Pharmaceutical Co Ltd |
Anti-axl antibody
|
MX2012001882A
(es)
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
US9260517B2
(en)
|
2009-11-17 |
2016-02-16 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
FR2958936A1
(fr)
|
2010-04-14 |
2011-10-21 |
Sanofi Aventis |
Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
|
US8906374B2
(en)
|
2010-04-20 |
2014-12-09 |
Cedars-Sinai Medical Center |
Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
|
SG186985A1
(en)
|
2010-07-09 |
2013-02-28 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
TWI560199B
(en)
*
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
EP2471543A1
(en)
*
|
2010-12-02 |
2012-07-04 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
|
JP2014501748A
(ja)
|
2010-12-21 |
2014-01-23 |
リコファーマ アーベー |
涙代用物
|
US20130331443A1
(en)
|
2010-12-22 |
2013-12-12 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
WO2012088445A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
WO2012085178A1
(en)
|
2010-12-23 |
2012-06-28 |
Sanofi |
Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
|
CN103476795B
(zh)
|
2011-03-29 |
2016-07-06 |
罗切格利卡特公司 |
抗体Fc变体
|
US20140088021A1
(en)
|
2011-05-27 |
2014-03-27 |
Nektar Therapeutics |
Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
|
EP2771694A4
(en)
|
2011-10-26 |
2015-08-05 |
Novartis Tiergesundheit Ag |
MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
|
EP2870247B1
(en)
|
2012-07-05 |
2019-06-26 |
F.Hoffmann-La Roche Ag |
Expression and secretion system
|
ES2690312T3
(es)
|
2012-07-13 |
2018-11-20 |
Roche Glycart Ag |
Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
|
RU2656162C2
(ru)
|
2012-10-22 |
2018-05-31 |
Фоунтейн Биофарма Инк. |
Антитела к интерлейкину 6 и их применение
|
ES2797376T3
(es)
|
2013-01-24 |
2020-12-02 |
Palvella Therapeutics Inc |
Composiciones para la administración transdérmica de inhibidores de mTOR
|
WO2014135984A2
(en)
|
2013-03-07 |
2014-09-12 |
Recopharma Ab |
Glycosylated mucin-immunoglobulin fusion protein coated device
|
JPWO2014189138A1
(ja)
*
|
2013-05-23 |
2017-02-23 |
Idacセラノスティクス株式会社 |
免疫不全ウイルス感染の治療又は予防剤
|
WO2015006519A1
(en)
*
|
2013-07-10 |
2015-01-15 |
The United States Of America, As Represented By The Secretary, Departement Of Health &Human Services |
Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans
|
BR112016006197B1
(pt)
|
2013-09-27 |
2023-04-11 |
Chugai Seiyaku Kabushiki Kaisha |
Método para produzir um anticorpo biespecífico de polipeptídeos
|
WO2015120198A1
(en)
|
2014-02-05 |
2015-08-13 |
Cedars-Sinai Medical Center |
Methods and compositions for treating cancer and infectious diseases
|
TWI759261B
(zh)
|
2015-02-27 |
2022-04-01 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
CN106188292B
(zh)
*
|
2015-05-05 |
2019-09-24 |
北京傲锐东源生物科技有限公司 |
抗cd4蛋白单克隆抗体及其用途
|
BR112018009312A8
(pt)
|
2015-12-28 |
2019-02-26 |
Chugai Pharmaceutical Co Ltd |
método para promover eficiência de purificação de polipeptídeo contendo região de fc
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
EP3565520A4
(en)
|
2017-01-06 |
2020-08-19 |
Palvella Therapeutics, Inc. |
Anhydrous compositions of MTOR inhibitors and method of use
|
EP3354278A1
(en)
|
2017-01-31 |
2018-08-01 |
Sanofi |
Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
|
CN108690138A
(zh)
*
|
2017-04-12 |
2018-10-23 |
鸿运华宁(杭州)生物医药有限公司 |
一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
WO2019160907A1
(en)
*
|
2018-02-14 |
2019-08-22 |
University Of Virginia Patent Foundation |
Regulating cd4+ t cells to treat clostridium difficile infection
|
TWI827585B
(zh)
|
2018-03-15 |
2024-01-01 |
日商中外製藥股份有限公司 |
對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
|
JP2021530463A
(ja)
|
2018-07-02 |
2021-11-11 |
パルヴェラ セラピューティクス、インク. |
mTOR阻害剤の無水組成物および使用方法
|
CN113244386A
(zh)
*
|
2020-02-13 |
2021-08-13 |
上海君实生物医药科技股份有限公司 |
抗pd-1抗体在治疗肿瘤中的用途
|
CN113248612A
(zh)
*
|
2020-02-13 |
2021-08-13 |
上海君实生物医药科技股份有限公司 |
抗pd-1抗体在治疗神经内分泌瘤中的用途
|
CN115197320A
(zh)
*
|
2021-04-07 |
2022-10-18 |
中美冠科生物技术(太仓)有限公司 |
新型抗cd4抗体
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
WO2023114949A1
(en)
|
2021-12-16 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and systems of particle production
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
WO2024112867A1
(en)
|
2022-11-23 |
2024-05-30 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods of use thereof for increasing immune responses
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|